相关实验视频

Updated: Jul 6, 2026

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Published on: June 9, 2014

通过使用多种优化策略,高效地扩大复合人体弹性素样多的生产规模

Jianwei Xiong¹, Longyin Liu¹, Wei Yu¹

¹Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China.

Journal of biotechnology

|February 22, 2025

概括

这项研究提出了一种高效,低成本的方法,用于生产复合人体弹性素样多 (rhELPs) 使用高细胞密度发酵和空洞纤维膜过. 开发的工艺实现了高产量和纯度,使生物医学应用的潜在工业规模生产成为可能.

科学领域:

生物技术是生物技术.
生物材料工程生物材料工程
再组合蛋白质的生产生产.

背景情况:

弹性类聚 (ELP) 是具有独特逆转变循环 (ITC) 特性的生物相容生物聚合物,使其适合生物医学用途.
现有的ELP生产方法产量低,净化复杂,阻碍了扩大规模的生产.
需要对ELP进行高效和成本效益的工业生产流程.

研究的目的:

开发一种高效,低成本的工业生产工艺,用于重组人体弹性类似多 (rhELP).
为大规模制造优化 rhELP 的表达和净化.
评估生产的 rhELP 的生物活性.

主要方法:

设计了一种Escherichia coli* (*E. coli*) 菌株,用于高rhelp表达,使用响应表面方法优化条件.
在自动化发酵器中采用高细胞密度发酵,以实现高产量.
开发了一种高效的净化策略,包括均化,花化,盐分,空腔纤维膜 (HFM) 过,离子交换色谱 (IEC) 和超过.

主要成果:

在自动发酵器中达到超过5.00g/L的rhELP产量,满足工业生产需求.
使用优化的多步骤工艺,净化 rhELP 达到 99.83% 的纯度,回收率为 80.40%.
已经证明,产生的rhELP是非细胞毒性,并促进伤口愈合,无论是*in vitro*还是*in vivo*.

结论:

这项研究为ELP和类似的重组蛋白的工业生产建立了一个通用范式.
开发的过程显著提升了生物医学应用有前途的ELP的商业化潜力.
这种高效且可扩展的生产方法克服了ELP制造的先前局限性.

关键词:

高细胞密度发酵的发酵方法空洞纤维膜过技术的技术.反向过渡循环的反向过渡循环.再组合的人类类弹性素类似的多.响应表面优化响应表面优化

更多相关视频

Design and Construction of Artificial Extracellular Matrix aECM Proteins from Escherichia coli for Skin Tissue Engineering

Design and Construction of Artificial Extracellular Matrix aECM Proteins from Escherichia coli for Skin Tissue Engineering

Published on: June 11, 2015

Production of Elastin-like Protein Hydrogels for Encapsulation and Immunostaining of Cells in 3D

Production of Elastin-like Protein Hydrogels for Encapsulation and Immunostaining of Cells in 3D

Published on: May 19, 2018

相关概念视频

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...